ADVERTISEMENT

ASCO 2022 – Circulating tumour DNA: is this the light to guide adjuvant therapy in colon cancer?

Cristina Ferrario — Agenzia Zoe   |   Conference Report   |   06 June 2022
ADVERTISEMENT

Takeaway

  • In patients with stage II colon cancer, an approach based on circulating tumour DNA (ctDNA) reduces the use of adjuvant chemotherapy without compromising recurrence risk.
  • ctDNA-positive patients are likely to benefit from adjuvant chemotherapy, while ctDNA-negative patients are not.

Why this matters

  • Surgery can cure more than 80% of...

          

January Challenge

Ends in 2d 14h
left
right

Topic Challenges

left
right